CClinicalTrials.gg
CompletedNCT01555255Updated Sep 17, 2026

Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria

An observational study in Malaria, Placental Malaria and Malaria in Pregnancy, sponsored by Foundation for Innovative New Diagnostics, Switzerland. Completed at 2 sites in 2 countries. Open to female participants aged 16 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Foundation for Innovative New Diagnostics, Switzerland · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,205
Ages
16 Years to 44 Years
Sex
Female
01

Study summary

This study seeks to determine whether screening pregnant women for malaria with malaria rapid diagnostic tests (RDTs) may detect placental infection and predict risk of poor birth outcomes due to malaria in areas of varied malaria transmission in Africa.

Read the detailed description

Malaria prevention measures for pregnant women are critical and available, but the effectiveness of intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine, a cornerstone in this prevention effort, is declining with increasing parasite resistance. New drugs for IPTp are being considered, but there are disadvantages to presumptive use of the few remaining efficacious antimalarials. An alternative approach may involve screening with diagnostic tests to better target efficacious antimalarial treatment to asymptomatic women with laboratory evidence of malaria infection. Light microscopy of peripheral maternal blood misses a large proportion of cases, and PCR is unavailable in routine health care settings. Preliminary evidence suggests that detection of parasite antigen in peripheral blood may provide an accurate indicator of clinically significant infections and predict pregnancy outcomes. Therefore, screening with RDTs may offer an accurate and practical way to identify pregnant women who will benefit from targeted therapy for placental malaria infection. Antigen detection thresholds vary widely among RDTs, and the distribution of target antigens in peripheral blood circulation is expected to differ; therefore, the potential value of RDTs in this population can best be established by evaluating the detection of placental parasitemia for highly-characterized RDTs, enabling results to be extrapolated to other products and programs. The study described here is proposed to address this question.

02

Conditions studied

  • Malaria
  • Placental Malaria
  • Malaria in Pregnancy

Keywords

  • malaria
  • pregnancy
  • placental malaria
  • malaria in pregnancy
  • birth weight
  • anemia
03

Who can participate

Ages eligible
16 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women presenting for routine antenatal care in the second and third trimesters of pregnancy, at antenatal clinics at ≥2 sites of varied malaria transmission intensity in Africa

Eligibility criteria

Specific participant selection criteria include:

  1. Presenting for care after quickening and before onset of labor (i.e. in the second or third trimester of pregnancy)
  2. Age between 16 years and 44 years, inclusive
  3. Willingness and ability to follow up with study visits and activities through the duration of pregnancy and at delivery
  4. Absence of history of serious adverse reaction to sulfa drugs
  5. Absence of history of serious adverse reaction to artemisinin-based drugs (depending on national policy on treatment of malaria in pregnancy)
  6. Absence of HIV infection (both because guidelines for malaria prevention in pregnancy for HIV-infected women differ from those for HIV-negative women, and in order to avoid confounding of pregnancy outcomes by HIV-related complications or treatments in this early evaluation)
  7. Absence of history of or current obstetrical complications (e.g. pre-eclampsia, eclampsia, hypertension during pregnancy, post-partum hemorrhage, evidence of multiple gestation)
  8. Absence of chronic disease (e.g. diabetes mellitus, sickle cell disease)
  9. Absence of evidence of severe acute disease requiring inpatient management or referral
  10. Provision of written informed consent
  11. Enrollment Hb ≥7 g/dL
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,205 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
05

What researchers measure

Primary outcomes

  1. accuracy of diagnostic tests during gestation

    accuracy of malaria RDTs, blood smears and PCR performed on maternal peripheral blood to diagnose or predict placental malaria during gestation

    Time frame: 2nd trimester of pregnancy

  2. accuracy of diagnostic tests during gestation

    accuracy of malaria RDTs, blood smears and PCR performed on maternal peripheral blood to diagnose or predict placental malaria during gestation

    Time frame: 3rd trimester of pregnancy

Secondary outcomes

  1. association of placental malaria with infant birth weight

    Time frame: at birth

  2. association of placental malaria with maternal hemoglobin

    Time frame: twice during gestation and at delivery

  3. accuracy of diagnostic tests at delivery

    accuracy of malaria RDTs, peripheral blood smears and PCR performed on maternal peripheral blood to diagnose placental malaria at delivery

    Time frame: at delivery

06

Study locations

2 sites
  • IRSS, Direction Régionale de l'Ouest
    Bobo-Dioulasso, 01BP 545, Burkina Faso
  • Tororo District Hospital
    Tororo, Tororo District 0, Uganda
07

References and documents

Publications

  • Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, Eam R, Chy S, Khean C, Loch K, Ken M, Lim H, Siv S, Tho S, Masse-Navette P, Gryseels C, Uk S, Van Roey K, Grietens KP, Sokny M, Thavrin B, Chuor CM, Deubel V, Durnez L, Coosemans M, Menard D. An innovative tool for moving malaria PCR detection of parasite reservoir into the field. Malar J. 2013 Nov 9;12:405. doi: 10.1186/1475-2875-12-405. PubMed 24206649 ↗
08

Registry details

Key details

Study ID
NCT01555255
Lead sponsor
Foundation for Innovative New Diagnostics, Switzerland
Collaborators
UNICEF, World Bank, World Health Organization
Responsible party
Sponsor
First posted
Mar 15, 2012
Start date
May 1, 2011
Primary completion
Mar 30, 2012
Completion
Mar 30, 2012
Last update
Sep 17, 2026

Study contacts

Heidi A Hopkins, MD
principal investigator · Foundation for Innovative New Diagnostics, Kampala, Uganda
Jean-Bosco Ouedraogo, MD, PhD
principal investigator · IRSS, Direction Regionale de l'Ouest, Bobo-Dioulasso, Burkina Faso
David Bell, MBBS, PhD
study director · Foundation for Innovative New Diagnostics, Geneva, Switzerland
Jane Cunningham, MD
study director · UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland
Miriam Nakalembe, MBChB
principal investigator · Makerere University Faculty of Medicine, Kampala, Uganda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion